TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) will likely be releasing its earnings data before the market opens on Monday, April 7th. Analysts expect TransCode Therapeutics to post earnings of ($3.21) per share and revenue of $0.30 million for the quarter.
TransCode Therapeutics Trading Down 0.9 %
Shares of RNAZ stock opened at $0.46 on Friday. TransCode Therapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $66.33. The stock has a 50 day moving average price of $4.60 and a two-hundred day moving average price of $208.04.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of TransCode Therapeutics in a report on Thursday, March 13th.
TransCode Therapeutics Company Profile
TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.
Featured Stories
- Five stocks we like better than TransCode Therapeutics
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Archer Aviation’s Africa Deal Could Boost ACHR Stock
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Are Short Sellers Wrong About These 3 Semiconductor Stocks?
- Most Volatile Stocks, What Investors Need to Know
- Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
